These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23807360)

  • 21. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.
    Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA
    Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
    Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of the pentavalent rotavirus vaccine in African infants.
    Armah GE; Breiman RF; Tapia MD; Dallas MJ; Neuzil KM; Binka FN; Sow SO; Ojwando J; Ciarlet M; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A86-93. PubMed ID: 22520142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
    Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
    Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants.
    Araujo EC; Clemens SA; Oliveira CS; Justino MC; Rubio P; Gabbay YB; da Silva VB; Mascarenhas JD; Noronha VL; Clemens R; Gusmão RH; Sanchez N; Monteiro TA; Linhares AC
    J Pediatr (Rio J); 2007; 83(3):217-24. PubMed ID: 17380232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
    Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.
    Vesikari T; Karvonen A; Puustinen L; Zeng SQ; Szakal ED; Delem A; De Vos B
    Pediatr Infect Dis J; 2004 Oct; 23(10):937-43. PubMed ID: 15602194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.
    Levin MJ; Lindsey JC; Kaplan SS; Schimana W; Lawrence J; McNeal MM; Bwakura-Dangarembizi M; Ogwu A; Mpabalwani EM; Sato P; Siberry G; Nelson M; Hille D; Weinberg GA; Weinberg A
    AIDS; 2017 Jan; 31(1):49-59. PubMed ID: 27662551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A short report on highlights of world-wide development of RIX4414: a Latin American experience.
    Linhares AC; Ruiz-Palacios GM; Guerrero ML; Salinas B; Perez-Schael I; Clemens SA; Innis B; Yarzabal JP; Vespa G; Cervantes Y; Hardt K; De Vos B
    Vaccine; 2006 May; 24(18):3784-5. PubMed ID: 16098636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.
    Steele AD; Neuzil KM; Cunliffe NA; Madhi SA; Bos P; Ngwira B; Witte D; Todd S; Louw C; Kirsten M; Aspinall S; Van Doorn LJ; Bouckenooghe A; Suryakiran PV; Han HH
    BMC Infect Dis; 2012 Sep; 12():213. PubMed ID: 22974466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.
    Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Thollot F; Garcia-Corbeira P; Damaso S; Han HH; Bouckenooghe A
    Vaccine; 2010 Jul; 28(32):5272-9. PubMed ID: 20538094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
    Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
    Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
    Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A short report on highlights of world-wide development of RIX4414: an European experience.
    Vesikari T; Karvonen A; Puustinen L; Szakal ED; Zeng SQ; Delem A; De Vos B
    Vaccine; 2006 May; 24(18):3779. PubMed ID: 16581159
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
    Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 °C for seven days.
    Kerdpanich A; Chokephaibulkit K; Watanaveeradej V; Vanprapar N; Simasathien S; Phavichitr N; Bock HL; Damaso S; Hutagalung Y; Han HH
    Hum Vaccin; 2011 Jan; 7(1):74-80. PubMed ID: 21228629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
    De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B
    Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.